Regulation of Blood Volume During Spaceflight by Alfrey, Clarence P.
206684
SLS-2 Final Report (NAG2-500) Experiment 141 Oq7
REGULATION OF BLOOD VOLUME DURING SPACEFLIGHT
Principal Investigator:
Clarence P. Alfrey, M.D.
Baylor College of Medicine
Department of Medicine
The Methodist Hospital
6565 Fannin, Mail Station 902 Main Bldg.
Houston, Texas 77030
Telephone: (713) 790-2157
Fascimile: (713) 790-0828
Co-Investigators:
Mark M. Udden
Theda Driscoll
Mark Pickett
Baylor College of Medicine
Houston, Texas
https://ntrs.nasa.gov/search.jsp?R=19980018073 2020-06-16T01:05:53+00:00Z
PI: ClarenceP.Alti-ey,M.D.
Grant#NAG2-500
Page 2
SUMMARY ABSTRACT
The effects of spaceflight on erythropoiesis and blood volume in the rat were studied during the
14-day NASA Spacelab Life Sciences 2 (SLS-2) Shuttle mission. Measurements included red
blood cell mass (RBCM), plasma volume (PV), iron utilization and iron utilization in response to
an injection of erythropoietin. Red blood cell (RBC) survival, splenic sequestration and
erythrocyte morphology were also evaluated. At landing, the RBCM adjusted for body weight
was significantly lower in the flight animals than in the ground controls. While the PV was also
decreased, the change was not statistically significant. Incorporation of iron into circulating RBCs
was normal when measured after five days of spaceflight and the rat responded normally to the
single in-flight injection of erythropoietin. No change in RBC morphology could be attributed to
spaceflight. A normal survival was found for the RBC population that was represented by 5 ICr
labeled RBCs. These results demonstrate that rats, like humans, return from spaceflight with a
decreased RBCM and total blood volume.
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OBJECTIVES
Human adaptation to microgravity during spaceflight is accompanied by a consistent loss of red
blood cell mass (RBCM), plasma volume (PV) and total blood volume (4, 8, 16). The reduction
in blood volume after exposure to microgravity has been attributed to the loss of gravity-dependent
spaces below the level of the heart that are ordinarily present in an upright individual (15). The
study of rats exposed to microgravity was undertaken to determine whether similar volume
changes occurred in these animals.
INTRODUCTION
Reassessment of blood volume changes in rats subjected to spaceflight is complicated by the
continued growth of the animal and the accompanying increase in RBCM and PV that occurs
during the mission. Numerous studies of rats subjected to spaceflight have examined peripheral
blood and bone marrow upon landing. The f'mdings have been reported to indicate decreased
erythropoiesis or no change (3, 5, 6, 7, 18). When our laboratory measured RBCM and PV
directly using radionuclide dilution methods on the 9-day SLS-1 mission, a clearer picture emerged
(17). Both the RBCM and PV of the flight animals were significantly decreased at the end of the
mission compared to controls when adjusted for body weight (ml per 100g). 59Fe incorporation
into RBCs indicated there was decreased erythropoiesis in the flight animals throughout the 8-day
post-flight observation period (17).
Here we report the results of a study of rats flown on the 14-day NASA Spacelab Life Sciences 2
Shuttle mission (SLS-2). In addition to pre- and post-flight determinations of RBCM and PV,
this study included the first in-flight measurements of PV and assessment of erythropoiesis. These
technically difficult experimental manipulations of rats, obtained under conditions of microgravity
by the SLS-2 crew members, enabled us to address three important questions raised by earlier
work: (1) Does plasma volume decrease significantly in the rat during spaceflight as it does in
humans?; (2) Is there evidence for decreased erythropoiesis during spaceflight and (3) Does the
bone marrow of the space-adapted rat have a normal response to exogenous erythropoietin, the
principal regulating hormone of erythropoiesis?
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MATERIALS AND METItODS
Animals. Male, specific pathogen-free, Sprague-Dawley rats supplied by Taconic Laboratories
(Indianapolis, IN) were flown on the shuttle Columbia during the SLS-2 mission (also designated
STS-58). The experimental design was approved by the animal care and use committees of Baylor
College of Medicine and the NASA Ames Research Center. The animals were handled in a
humane manner under the supervision of a veterinarian and in accordance with national and
international standards. A veterinarian also participated as a crew member during the 14-day flight.
The animals were housed in Florida at the Kennedy Space Center (KSC) vivarium facility for four
weeks prior to launch. Fifteen animals were selected for spaceflight and 15 were selected to be
ground controls. During the flight, the animals were housed in the Research Animal Holding
Facility (RAHF). The RAHF provided automatic temperature and humidity control, a waste
management system and food and water upon demand. Due to an in-flight adjustment of
temperature control, the ambient temperature during the flight was 28 °C. The 15 ground control
animals were maintained at a similar temperature in simulated RAHF cages. One day after launch,
the controls were transferred by airplane to the shuttle landing site and housed at the Dryden
Payload Receiving Facility (PRF), Edwards Air Force Base, California. Animals were housed in
individual cages and were on an automatic 12/12 lighting cycle throughout the study.
Seven days prior to launch, both the flight and control animals underwent determinations of PV
and RBCM by radionuclide dilution methods. On flight day six (FD6), one group of five animals
received injections of 125I-labeled albumin and 59Fe-ferrous citrate. Samples were taken ten
minutes later for PV determination and 24 hours later for determination of 59Fe incorporation into
RBCs. on FD9, the remaining 10 animals received an injection of 59Fe. Half of these animals
were given a 200U bolus of recombinant human erythropoietin (rhEPO), (Epogen, Amgen,
Thousand Oaks, CA). The other half received a saline injection of the same volume. Procedures
were performed concurrently on flight and ground control animals. On the day of landing, the
following determinations were made for all flight and ground control animals: PV, RBCM, 5 _Cr
spleen to liver ratio, 51Cr RBC survival, and percentage of 59Fe incorporated into RBCs. The
post-flight samples for these determinations were obtained 3 to 6 hours after landing. Animals
were weighed daily during the pre-flight period, twice during the flight and upon return to earth.
Red blood cell mass and plasma volume determinations. Previously described radionuclide
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dilution methods were used to determine the RBCM and PV (13). Briefly, for each pre- and post-
flight PV determination, 1 taCi of 12SI-labeled albumin in a volume of 0.1 ml was injected. 51Cr-
labeled RBCs were used for the RBCM determinations. Blood obtained by cardiocentesis from
one or two donor rats was incubated with S_Cr-sodium chromate and the RBCs were then washed
and diluted with saline. The final concentration of 51Cr was 5 jaCi per 0.2 ml and the hematoerit
was 55%. The radiolabels were injected at the same time in a volume of 0.3 ml and a blood sample
was obtained 10 minute after the injection. For the in-flight PV determinations, 1 laCi of 125I-
labeled albumin in a volume of 0.4 ml was injected. Pediatric catheters were placed in the tail vein
to obtain a background blood sample and make an injection (14). The post-injection blood sample
was obtained with a second venipuncture in a contra-lateral tail vein. The volume of blood required
was less than 0.3 ml for the background, the 10 minute sample and an aliquot provided to other
investigators participating in this mission.
59Fe incorporation into circulating red blood cells. Three _tCi of S9Fe-ferrous citrate in a volume of
0.4 ml was injected intravenously. Blood samples were obtained 24 hours after injection to
determine the early incorporation rate and on landing day to determine the maximum amount
incorporated. This maximum value was determined at 9 days after the FD6 injection and at 6 days
after the FD9 injection. The values are expressed as the percentage of SgFe in total circulating
RBCs, i.e., net counts per minute (NCPM) per ml of RBCs times RBCM divided by NCPM 59Fe
injected. The RBCM determined on landing day was used in the maximum value calculation and
the body mass was used to estimate RBCM for calculation of the 24 hour value. A linear change
between pre-flight and post-flight values of RBCM per 100 grams body weight was assumed for
the estimates of the in-flight RBCM values (1, 9).
In addition to the 59Fe injection on FD9, half of the animals were scheduled to be injected IV with
200 units rhEPO and the other half with an equal volume of saline. On FD9, the in-flight
injections proved to be technically difficult in two animals. Venous catheter placement was not
achieved in one and a sub optimal injection was noted in the crew experiment log for a second
animal. Subsequent measurement of iron incorporation confirmed the minimal administration of
59Fe to that animal. Both of these animals were in the saline injection group, leaving this group
with three animals instead of the five that was originally planned.
51Cr-l_bele¢l donor RBC survival and spleen sequestration. Because of the growth of the animals
and the concomitant increase in RBCM, the estimate of RBC survival was based upon total
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circulating 51Cr, i.e., NCPM per ml RBC times RBCM. This value was determined twice, once at
the start of the study when the 51Cr-labeled RBCs were injected 7 days pre-flight and again on
landing day when a second RBCM was determined. On the basis of these two data points, the
RBC survival TI/2 was estimated in days.
On landing day, the liver and spleen were removed at dissection. The total organ weights were
obtained, a tissue sample from each organ was weighed and the 51Cr activity of the sample was
determined. The total organ 51Cr content was calculated (NCPM per gram times total organ weight
in grams). The ratio of spleen to liver 51Cr radioactivity was calculated.
RBC morphology. A drop of blood from the tail vein venipuncture was added to 1.0 ml of 0.5%
glutaraldehyde in phosphate buffered normal saline containing 1.13 mM calcium and 1.0 mM
magnesium chloride buffer. Samples were obtained pre-, in- and post-flight. Later these were
mounted wet on glass slides under cover slips and examined under light microscopy at 1000x
magnification. One thousand cells were counted to determine the number of normal RBCs
(discocytes) and spiculated ceils (echinocytes).
In-flight experiment ea(lm__mg0_t. Procedures were carried out within the General Purpose Work
Station (GPWS), a glove box designed for the Spacelab. Experimental supplies for blood
sampling and injections were contained in special in-flight kits designed by the NASA Ames
Research Center for use in microgravity. The Small Mass Measurement Instrument (SMMI) was
used to determine rodent body mass.
Statistical methods. Data are expressed as means + SE for the ground control and the flight
animals. Statistical analysis included the Repeated Measurements ANOVA, One Factor ANOVA
and Bonferroni - Dunn test. A nonparametric statistical test, the Mann-Whitney U was applied
when the number of observations per group was less than 5. Statistical significance was set at the
p <_0.05 level.
RESULTS AND DISCUSSION
Shown in Figure 1 are the growth curves for the flight and ground control animals. Below 150
grams the two groups had identical growth rates but for the remainder of the pre-flight period the
control group gained weight at a slightly faster rate while during the mission the flight animals
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grew at a faster rate. The difference was not statistically significant during the pre-flight period
but was during flight.
Shown in Figure 2 are the pre- and post-flight RBCM and PV results expressed as absolute
volume (A, B) and as volume normalized for body weight (C, D). Rats injected with rhEPO were
not included in the calculation of these means (n=10). The absolute volume of RBCM and PV
increased due to the growth of the animals during the 21 days between measurements. The
absolute RBCM measured in the flight animals on landing day was smaller than the control value.
When RBCM was normalized for weight, there was a significant difference between the flight
animals and the ground controls. No significant difference was found between the control and
flight animals when the PV was expressed as an absolute volume or when normalized for body
weight. Statistical analysis of the weight normalized total blood volume, i.e., RBCM plus PV,
showed that on the day of landing, the flight animal mean (6.25 + .09 ml/100 g) was significantly
less than the control mean (6.69 +__.08 ml/100 g).
Shown in Figure 3 are the mean PVs normalized for weight for the 5 flight and 5 ground control
animals that had additional PV determinations on FD6 and 8 days post-flight. The flight group
mean was smaller than the control mean at each determination but at no time was the difference
significant.
59Fe RBC incorporation values after the FD6 injection are shown in Figure 4. Mean values are
shown for 24 hours and 9 days post-injection (landing day). There was no significant difference
between the flight animals and the ground control animals and the values were within normal
limits. Following the FD9 injection, 59Fe incorporation values were within normal limits except
for the 24 hour mean of the ground control animals injected with saline (Figure 5). This mean was
statistically less than the other 24 hour values of this study and our normal values when identical
methods were used to determine RBC incorporation of iron during ground based flight experiment
verification tests. In one ground based study the 24 hour mean _+ SE was 37 _+ 1% for 5 animals
injected with saline and 44 + 4 % for 5 animals injected with rhEPO. As indicated in Figure 5, the
24 hour mean value for flight animals injected with rhEPO was significantly greater than the mean
for flight animals injected with saline. The mean values on the sixth day post-injection (landing
day) were normal and there was no difference between groups.
The survival of RBCs labeled with 51Cr 7 days prior to launch was not affected by spaceflight.
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The mean _+ SE of the Tj/2 was 19.6 _+ 1.3 days for the ground controls and 20.3 _+ 1.0 days for
the flight animals. There was no increased splenic sequestration of these cells. The mean +_ SE of
the 5JCr spleen to liver ratio was 1.5 +_ 0.2 for the controls and 1.6 _+0.2 for the flight animals.
No change relative to spaceflight was found in the number of echinocytes or other non-discocytes
(Data not shown). There was considerable daily variability in the proportions of these cells in
both the flight and ground control animals.
At the end of this 14-day mission, RBCM normalized for body weight was significantly decreased
in the flight animals compared to ground controls and these results confirm our findings for the 14
rats that flew on the 9-day SLS-1 mission (17). While PV normalized for the weight of the animal
showed no statistically significant flight-related difference, the changes were in the same direction
as the significantly decreased PV that was found for the rats that flew on the SLS-1 mission (17).
The absence of a significant change in PV after 6 days of spaceflight indicates that the decrease in
total blood volume of the rat is not accompanied by the same marked reduction in PV that is seen
when humans adapt to microgravity (16).
Erythropoiesis was evaluated by measuring the incorporation of radiolabeled iron into circulating
RBCs during exposure to microgravity. In-flight 59Fe studies on FD6 and FD9 indicate that
utilization of iron by the bone marrow was at the same level as in ground based studies of normal
rats. A 24-hour RBC incorporation rate of about 40% and a maximum plateau between 65 and
75% by three days post-injection have been reported (2, 9, 12). We have no explanation for the
low 24-hour mean value of 29% that was found for the ground control group after the FD9
injection. An increased 24-hour incorporation rate in response to the injection of rhEPO
demonstrates that erythropoiesis is stimulated normally by this hormone under conditions of
microgravity. These results are consistent with the presence of a marrow that is actively using iron
and releasing 59Fe-labeled RBCs into the circulation at a normal rate.
This was the first time that erythropoiesis in the rat has been studied in-flight. The bone marrow
of rats flown aboard Cosmos biosatellite missions of 5 to 22 days duration has been studied post-
flight and evidence of decreased erythropoiesis has been reported (3, 5, 18). When bone marrow
cells were cultured in vitro with EPO after the SL-3 mission, there were increases in the number of
BFU-e and CFU-e colonies in flight animals (6) while results from SLS-I showed a decrease in
the number of these colonies (17). Also, iron utilization by RBCs was decreased throughout an 8-
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day post-flight period (17). These reported post-flight changes may have been affected by the
stress associated with re-entry and landing since studies reported here indicate a normal marrow
from the 6th day of spaceflight to the end of the mission.
A RBC precursor, 14C-glycine, was used to study rats flown on two 19-day Cosmos biosatellite
missions. The findings indicted accelerated hemolysis during some portion of the mission and a
shortened RBC life-span was reported (10, 11). We found no change in RBC survival or splenic
sequestration ofSlCr-labeled RBCs during this mission or the SLS-1 mission (17). The spleen to
liver ratio reflects the cumulative deposition of all 51Cr-labeled RBCs that were removed from
circulation from the pre-flight injection day to landing day. If the survival of 51Cr_labele d RBCs
had been shortened by exposure to microgravity, then the spleen to liver ratio would have been
larger in the flight animals. RBCs that were produced after the injection of the labeled RBCs were
not represented in our 51Cr survival measurements. The survival of this small sub-population of
young cells can not be ascertained from our studies.
CONCLUSIONS
Our results demonstrate that rats, like humans, return from spaceflight with a RBCM and total
blood volume that is less than it would have been if they had remained on earth. The absence of a
significant change in PV during the mission indicates that the regulation of total blood volume in
the rat is not the same as it is in humans.
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FIGURE LEGENDS
Figure 1. Growth curves for animals from 22 days prior to launch through landing day (R+0).
Values are Mean _+ SE; n = 10. During the mission and on landing day there was a significant
difference between the flight means and the ground control means as shown by Repeated
Measurements ANOVA and Bonferroni - Dunn test with p <_ 0.05.
Figure 2. A. RBCM as absolute volume; B. PV as absolute volume; C. RBCM normalized
for body weight; D. PV normalized for body weight. Values are Mean _.+SE; n = 10. The (*)
indicates a significant difference between the flight mean and the ground control mean as shown by
Repeated Measurements ANOVA and Bonferroni - Dunn test with p < 0.05.
Figure 3. Plasma volume normalized for body weight. Values are Mean + SE; n = 5. Repeated
Measurements ANOVA showed no significant difference related to spaceflight.
Figure 4. Percentage 59Fe incorporated into total circulating RBCs after FD6 injection. Values
are Mean + SE; n = 5. Values for both groups at 24 hours and 9 days were within the normal
range and no difference was found between ground control and flight animals.
Figure 5. Percentage 59Fe incorporated into total circulating RBCs after FD9 injection. Values
are Mean + SE; n = 5 (exception n=3 for saline injected flight animals). The (*) indicates a
significant difference between the 24-hour ground control mean and all other 24-hour means as
shown by One Factor ANOVA and Bonferroni - Dunn test with p 5_ 0.05. The (**) indicates a
significant difference between the EPO injected and saline injected flight animals at 24 hours as
shown by the Mann-Whitney U test with p <_ 0.05.
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SLS 2 - Exp. 141 Data
Body Mass On Days When Radionuclide Measurements Were Made
grams
FLIGItT ANIMALS GROUND CONTROL ANIMALS
I.D. L-7 FD6 FD10 R+0 R+8 I.D. L-7 FD6 FD10 R+0 R+8
Group 1 14 228 316 353 346 327 20 231 315 327 357
76 228 326 328 348 350 66 223 272 265 252
13 206 290 298 313 321 72 209 290 286 302
18 211 297 320 330 338 17 239 253 282 321
24 211 305 330 347 343 16 230 278 297 316
Group 2 28 227 320 355 371 73 228 286 295 317
29 203 270 276 281 74 222 263 269 301
58 243 318 348 365 54 233 275 313 341
3 211 286 308 314 59 231 291 298 313
83 225 276 297 316 62 230 275 280 294
Group 3 27 237 337 356 373 2 234 285 313 351
30 209 300 328 347 10 239 320 344 382
51 235 327 349 367 53 215 286 301 313
68 222 294 319 333 57 233 297 325 355
81 230 323 345 359 61 236 308 319 345
385
294
323
363
371
Group 1 Mean 217 307 326 337 336 227 281 291 309 347
SE 5 7 9 7 5 5 10 10 17 17
Group 2 Mean 222 294 317 329 229 278 291 313
SE 7 11 15 17 2 5 8 8
Group 3 Mean 227 316 339 356 232 299 320 349
SE 5 8 7 7 4 7 7 11
Group 1,2,3 Mean 222 306 327 341 229 286 301 324
SE 3 5 6 7 2 5 6 8
Group 1,2 Mean 219 301 321 333 228 280 291 311
SE 4 6 8 9 3 5 6 9
Group 1 125-I Albumin and 59-Fe injection on FD6 Saline dilutent -
Group 2 59-Fe and saline injection on FD9 Saline dilutent -
Group 3 59-Fe and EPO injection on FD9 Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 m/:
total volume injected 1.2 ml
D-1
SLS 2 - Exp. 141 Data
PLASMA VOLUME
milliters
FLIGHT ANIMALS GROUND CONTROL ANIMALS
I.D. L-7 FD6 R+0 R+8 I.D. L-7 FD6 R+0 R+8
Group 1
Group 2
Group 3
14 10.80 11.37 13.20
76 9.50 7.92 12.60
13 9.76 12.09 13.80
18 9.62 11.09 11.90
24 9.14 11.81 13.30
28 9.87 15.80
29 8.54 11.60
58 11.24 13.80
3 9.34 13.10
83 9.57 12.50
27 - 14.10
30 8.74 12.60
51 10.84 14.40
68 10.10 14.20
81 10.07 13.30
9.85
12.00
9.79
10.44
10.36
20 10.99 13.22 15.20
66 9.75 8.92 10.10
72 10.94 10.10 12.30
17 11.59 7.96 13.40
16 9.85 10.87 13.60
73 9.97 12.10
74 9.39 13.40
54 10.97 14.60
59 9.82 11.70
62 9.81 11.40
2 10.87 14.20
10 11.05 14.50
53 10.27 12.50
57 9.86 14.40
61 10.69 14.30
13.56
9.40
11.15
12.43
12.10
Group 1 Mean 9.76 10.86 12.96 10.49
SE 0.28 0.75 0.33 0.40
10.62 10.21 12.92 11.73
0.36 0.90 0.84 0.70
Group 2 Mean 9.71 13.36
SE 0.44 0.71
9.99 12.64
0.26 0.60
Group 3 Mean 9.94 13.72
SE 0.44 0.34
10.55 13.98
0.22 0.37
Group 1, 2, 3 Mean 9.80 13.35
SE 0.21 0.28
10.39 13.18
0.17 0.37
Group 1, 2 Mean 9.74 13.16
SE 0.25 0.37
10.31 12.78
0.23 0.49
Group I
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 m/
total volume injected 1.2 ml
D-2
SLS 2 - Exp. 141 Data
PLASMA VOLUME
ml per 100 g body weight
FLIGHT ANIMALS GROUND CONTROL ANIMALS
I.D. L-7 FD6 R+0 R+8 I.D. Pre FD6 Landing R+8
Group 1
Group 2
Group 3
14 4.74 3.60 3.82
76 4.17 2.42 3.62
13 4.74 4.17 4.39
18 4.56 3.73 3.59
24 4.33 3.87 3.82
28 4.35 4.26
29 4.21 4.11
58 4.62 3.78
3 4.43 4.17
83 4.25 3.95
27 3.78
30 4.18 3.65
51 4.61 3.91
68 4.55 4.26
81 4.38 3.70
3.52
3.20
3.45
3.42
3.26
20 4.76 4.20 4.26
66 4.37 3.28 4.00
72 5.23 3.48 4.08
17 4.85 3.15 4.17
16 4.28 3.91 4.29
73 4.37 3.81
74 4.23 4.46
54 4.71 4.27
59 4.25 3.74
62 4.26 3.90
2 4.65 4.06
10 4.62 3.79
53 4.78 4.00
57 4.23 4.05
61 4.53 4.14
3.01
3.43
3.05
3.09
3.02
Group 1 4.51 3.56 3.85 3.37
0.11 0.30 0.14 0.06
4.70 3.60 4.16 3.12
0.17 0.20 0.05 0.08
Group 2 4.37 4.05
0.07 0.09
4.36 4.04
0.09 0.14
Group 3 4.43 3.86
0.10 0.11
4.56 4.01
0.09 0.06
Group 1, 2, 3 4.44 3.92
0.05 0.07
4.54 4.07
0.08 0.05
Group 1, 2, 4.44 3.95
0.07 0.09
4.53 4.10
0.11 0.07
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total vohtme injected 1.2 ml
total volume injected 1.2 ml
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RED BLOOD CELL MASS
milliliters
FLIGHT ANIMALS
I.D. L-7 R+0
Group I 14 5.98 8.59
76 5.35 8.64
13 5.15 6.87
18 4.92 7.89
24 5.56 7.0O
Group 2 28 5.27 8.80
29 5.07 6.39
58 5.61 7.54
3 4.94 7.43
83 5.99 7.21
Group 3 27 9.79
30 4.73 6.85
51 5.99 8.23
68 5.47 8.03
81 5.40 9.30
Group 1
Group 2
Group 3
Group 1, 2, 3
Group 1, 2
Mean 5.39 7.80
SE 0.18 0.38
Mean 5.38 7.47
SE 0.19 0.39
Mean 5.40 8.44
SE 0.26 0.51
Mean 5.39 7.90
SE 0.11 0.25
Mean 5.38 7.64
SE 0.12 026
GROUND CONTROL ANIMALS
I.D. L-7 R+0
20 5.30 8.65
66 5.47 6.99
72 5.38 7.62
17 5.58 7.33
16 5.68 7.14
73 5.39 8.40
74 5.28 8.55
54 5.52 9.88
59 5.14 9.66
62 5.47 7.44
2 5.64 8.58
10 5.44 9.14
53 5.49 11.78
57 5.67 8.70
61 6.34 9.94
Mean 5.48 7.55
SE 0.07 0.30
Mean 5.36 8.79
SE 0.07 0.45
Mean 5.72 9.63
SE 0.16 0.59
Mean 5.52 8.65
SE 0.07 0.34
Mean 5.42 8.17
SE 0.05 0.33
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
\
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RED BLOOD CELL MASS
milliliters per 100 grams body weight
FLIGHT ANIMALS
I.D. L-7 R+0
Group 1 14 2.62 2.48
76 2.35 2.48
13 2.50 2.20
18 2.33 2.39
24 2.63 2.02
Group 2 28 2.32 2.37
29 2.50 2.28
58 2.31 2.06
3 2.34 2.37
83 2.66 2.28
Group 3 27 2.62
30 2.26 1.97
51 2.55 2.27
68 2.46 2.4I
81 2.35 2.59
Group 1
Group 2
Group 3
Group 1, 2, 3
Group 1,2
Group 1
Group 2
Group 3
Mean 2.49 2.31
SE 0.06 0.09
Mean 2.43 2.27
SE 0.07 0.06
Mean 2.41 2.37
SE 0.06 0.12
Mean 2.44 2.32
SE 0.04 0.05
Mean 2.46 2.29
SE 0.05 0.05
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
GROUND CONTROL ANIMALS
I.D. L-7 R+0
20 2.29 2.42
66 2.46 2.77
72 2.58 2.52
17 2.33 2.28
16 2.47 2.26
73 2.37 2.65
74 2.38 2.84
54 2.37 2.90
59 2.22 3.09
62 2.38 2.53
2 2.41 2.45
10 2.28 2.39
53 2.56 3.76
57 2.44 2.45
61 2.69 2.88
Mean 2.43 2.45
SE 0.05 0.09
Mean 2.34 2.80
SE 0.03 0.10
Mean 2.48 2.79
SE 0.07 0.26
Mean 2.42 2.68
SE O.03 0.10
Mean 2.39 2.63
SE 0.03 0.09
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
D-5
SLS 2 - Exp. 141 Data
FLIGHT ANIMALS
BLOOD VOLUME
milliliters
I.D. L-7 R+0
Group I 14 16.78 20.65
76 14.85 20.59
13 14.91 18.83
18 14.54 18.44
24 14.70 18.91
Group 2 28 15.14 22.79
29 13.61 16.76
58 16.85 20.08
3 14.28 19.01
83 15.56 18.27
Group 3 27 22.64
30 13.47 18.31
51 16.83 20.97
68 15.57 20.36
81 15.47 20.62
Group I
Group 2
Group 3
Mean 15.16 19.48
SE 0.41 0.47
Mean 15.09 19.38
SE 0.56 1.01
Mean 15.34 20.58
SE 0.69 0.69
Mean 15.18 19.82
SE 029 0.43
Mean 15.12 19.43
SE 0.33 0.53
Group 1, 2, 3
Group 1, 2
GROUND CONTROL ANIMALS
I.D. L-7 R+0
20 16.29 22.06
66 15.22 16.05
72 16.32 18.87
17 17.17 19.56
16 15.53 19.23
73 15.36 19.40
74 14.67 20.75
54 16.49 23.00
59 14.96 20.12
62 15.28 17.47
2 16.52 21.19
10 16.49 22.21
53 15.76 23. l 1
57 15.53 22.00
61 17.03 23.20
Mean 16.11 19.15
SE 0.34 0.96
Mean 15.35 20.15
SE 0.31 0.90
Mean 1627 22.34
SE 027 0.37
Mean 15.91 20.55
SE 020 0.55
Mean 15.73 19.65
SE 025 0.64
Group 1
Group 2
Group 3
125-1 Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
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BLOOD VOLI_I-_IE
milfiliters PER 100 gram body mass
FLIGHT AMMALS
I.D. L-7 R+0
Group I 14 7.36 5.97
76 6.51 5.92
13 7.24 6.02
18 6.89 5_59
24 6.97 5.45
Group 2 28 6.67 6.14
29 6.70 5.96
58 6.93 5.50
3 6.77 6.05
83 6.92 5.78
Group 3 27 6.07
30 6.44 5.28
51 7.16 5.71
68 7.01 6.11
81 6.73 5.74
Group ! Mean 6.99 5.79
SE 0.15 0.11
Group 2 Mean 6A0 5.89
SE 0.05 0.1!
Group 3 Mean 6.84 5.78
SE 0.16 0.15
Group 1, 2, 3 Mean
SE
6_8 5.82
0.07 0.07
Group 1, 2 Mean 6.90 52_4
SE 0.08 0.08
GROUND CONTROL ANIMALS
I.D. L-7 R+0
20 7.05 6.18
66 6.83 6.37
72 7.81 6.25
17 7.18 6.09
16 6.75 6.09
73 6.74 6.12
74 6.61 6.89
54 7.08 6.74
59 6.48 6.43
62 6.64 5.94
2 7.06 6.04
10 6.90 5.81
53 7.33 7.38
57 6.67 6.20
61 7.22 6.72
Mean 7.12 6.20
SE 0.19 0.05
Mean 6.71 6.43
SE 0.10 0.18
Mean 7.03 6.43
SE 0.12 0.28
Mean 6.96 6._5
SE 0.09 0.11
Mean 6.92 6.31
SE 0.12 0.10
Group 1
Group 2
Group 3
125-I Albu_nin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
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Total Body Hematocrit
Percentage
FLIGHT ANIMALS GROUND CONTROL ANIMALS
I.D. L-7 R+0 I.D. L-7 R+0
Group 1 14 35.6 42.2
76 36.0 44.0
13 34.5 37.2
18 33.8 42.4
24 37.8 37.8
Group 2 28 34.8 39.3
29 37.3 39.0
58 33.3 38.6
3 34.6 39.6
83 38.5 39.3
Group 3 27 43.5
30 35.1 38.0
51 35.6 40.3
68 35.1 39.4
81 34.9 44.2
20 32.5 40.1
66 35.9 44.4
72 33.0 41.0
17 32.5 38.2
16 36.6 37.8
73 35.1 44.0
74 36.0 42.4
54 33.5 43.8
59 34.4 47.9
62 35.8 43.1
2 34.2 41.0
10 33.0 42.3
53 34.8 51.8
57 36.5 40.9
61 37.2 44.3
Group 1 Mean 35.6 40.7
SE 0.7 1.4
Mean 34.1 40.3
SE 0.9 1.2
Group 2 Mean 35.7 39.2
SE 0.9 0.2
Mean 34.9 44.2
SE 0.5 1.0
Group 3 Mean 35.2 41.1
SE 0.1 1.2
Mean 35.2 44.1
SE 0.8 2.0
Group 1, 2, 3 Mean 35.5 40.3
SE 0A 0.6
Mean 34.7 42.9
SE 0.4 0.9
Group 1, 2 Mean 35.6 39.9
SE 0.6 0.7
Mean 34.5 42.3
SE 0.5 1.0
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
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Total Body to Peripheral Hematocrit Ratio
FLIGHT ANIMALS GROUND CONTROL ANIMALS
I.D. L-7 R+0 I.D. L-7 R+0
Group I 14 0.77 0.82
76 0.77 0.84
13 0.78 0.79
18 0.77 0.86
24 0.80 0.77
Group 2 28 0.78 0.78
29 0.82 0.82
58 0.77 0.80
3 0.78 0.81
83 0.85 0.80
Group 3 27 0.89
30 0.76 0.79
51 0.78 0.80
68 0.78 0.81
81 0.78 0.89
20 0.77 0.81
66 0.76 0.79
72 0.77 0.81
17 0.77 0.80
16 0.72 0.79
73 0.75 0.85
74 0.73 0.88
54 0.82 0.90
59 0.78 0.95
62 0.79 0.82
2 0.73 0.80
10 0.75 0.84
53 0.74 0.98
57 0.78 0.78
61 0.8i 0.85
Group 1 Mean 0.78 0.81
SE 0.01 0.01
Mean 0.76 0.80
SE 0.01 0.01
Group 2 Mean 0.80 0.80
SE 0.02 0.01
Mean 0.77 0.88
SE 0.02 0.02
Group 3 Mean 0.77 0.84
SE 0.01 0.02
Mean 0.76 0.85
SE 0.01 0.03
Group 1, 2, 3 Mean 0.78 0.82
SE 0.01 0.01
Mean 0.77 0.84
SE 0.01 0.02
Group 1, 2 Mean 0.79 0.81
SE 0.01 0.01
Mean 0.77 0.84
SE 0.01 0.02
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
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LB.
14
76
13
18
24
Mean
SE
l.n.
28
29
58
3
83
Mean
SE
I.D.
27
30
5l
68
81
Mean
SE
IRON INCORPORATION INTO RED BLOOD CELLS
% 59-Fe in Total Red Blood Cell Mass
FLIGHT ANIMALS GROU,'ND CONTROL ANIMALS
Group I - 59-Fe Injection on FD6
FD7 R+0 FD7
24 Hours 9Days I.D. 24 Hours
R+0
9Days
20.5 76.9 20 53.1
43.4 64.4 66 26.9
51.1 59.2 72 39.7
40.6 75.3 17 32.7
34.3 61.3 16 55.8
74.7
66.4
70.2
68.6
68.7
38.0 67.4 glean 41.6
5.1 3.6 SE 5.6
69.7
1.4
Group 2 - 59-Fe and Saline Injection on FD9
FD10 R+0 FD10
24 Hours 6 Days I.D. 24 ilours
R+0
6 Days
42.2 69.7 73 36.4
74 26.3
54 30.9
43.1 72.6 59 24.7
44.8 72.7 62 27.6
74.1
69.2
74.8
77.7
69.2
43.4 71.7 Mean 29.2
0.8 1.0 SE 2.1
73.0
1.7
Group 3 - 59-Fe and Erythropoietin Injection on FD9 (200 Units EPO)
FD10 R+0 FD10
24 Hours 6 Days I.D. 24 Hours
R+0
6 Days
48.9 77.7 2 35.7
50.5 62.0 10 52.0
49.7 64.2 53 36.9
43.9 70.6 57 50.5
53.0 84.7 61 46.8
66.4
75.2
99.8
70.5
84.9
49.2 71.8 Mean 44.4
1.5 4.2 SE 3.4
79.4
6.0
D-12
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Group 1
Group 2
Group 3
Group 1
Group 2
Group 3
Group 1, 2, 3
Group 1, 2
51-Cr RED BLOOD SUR_vIVAL
TII2 in Days
FLIGHT ANIMALS GROUND CONTROL ANIMALS
I.D. L-6
to
R+0
14 21.0
76 21.0
13 18.0
18 21.5
24 18.2
28 18.4
29 18.5
58 23.8
3 20.6
83 17.6
27
30 23.0
51 18.0
68 22.0
81 23.5
R+I
to
R+8
18.9
17.7
16.9
20.3
22.1
I.D. L-6
to
R+0
20 21.5
66 17.2
72 17.0
17 23.2
16 18.2
73 17.6
74 18.1
54 17.8
59 20.9
62 16.9
2 20.1
10 19.4
53 19.5
57 17.6
61 17.7
Mean 19.9 19.2
SE 0.8 0.9
R+I
to
R+8
17.9
18.7
22.9
18.0
19.3
Mean 19.8
SE 1.1
Mean 19.4 19.4
SE 1.2 0.9
Mean 21.6
SE 1.2
Mean 18.3
SE 0.7
Mean 20.4
SE 0.6
Mean 18.9
SE 0.5
Mean 19.9
SE 0.6
Mean 18.8
SE 0.5
Mean 18.8
SE 0.7
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
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Group 1
Group 2
Group 3
51-CR SPLEEN TO LIVER RATIO
FI,IGIIT ANIMALS
I.D. R+9
14 1.58
76 1.46
13 2.84
18 2.55
24 2.73
Mean 2.23
SE 0.29
RAT # R+0
28 1.36
29 1.34
58 1.14
3 1.93
83 2.23
Mean 1.60
SE 0.21
27
30 1.64
51 2.40
68 1.13
81 2.04
Mean 1.80
SE 0.27
GROUND CONTROL ANIMALS
I.D. R+9
20 3.02
66 2.97
72 2.63
17 2.99
16 1.98
2.72
0.20
RAT # R+0
73 1.32
74 1.32
54 1.43
59 1.34
62 2.32
1.54
0.20
2 1.37
10 0.46
53 0.56
57 1.38
61 1.17
Mean 0.99
SE 0.20
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 rnl
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Group 1
Group 2
Group 3
Group 1
Group 2
Group 3
Group 1,2,3
Group 1,2
PLASMA FERRITIN
ng per dl
GROUND CONTROL ANIMALS
I.D. L-7 L-6 FD6 FD7 FD9 FDI0 FDI4 R+0 R+2 R+4 R+6
20 278 196 884 707 669 454
66 309 323 781 1017 715 528
72 312 632 958 1550 814 433
17 322 319 1371 1281 729 408
16 348 525 942 1235 734 668
73 660 693 921 805 478
74 730 1065 748 448
54 717 512 933 784 549
59 475 244 1006 1121 417
62 548 546 1009 826 670
2 848 463 1598 498
10 404 580 794 730 462
53 542 587 1766 1613 595
57 446 378 1054 1135 463
61 395 486 1146 1637 552
258 267 369
782 583 397
429 378 249
* 442 361
550 843 473
Mean 314 399 987 1158 732 498 505 503 370
SE 11 79 101 141 23 47 99 99 36
Mean 626 499 987 857 512
SE 50 84 27 67 45
Mean 527 499 1190 1343 514
SE 84 39 184 179 26
Mean 489 463 508
SE 46 39 22
Mean 543 473 520
SE 53 52 35
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilutent -
Saline dilutent -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
The elevated values for in-flight days may be due to an artifact of sample storage.
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Group 1
Group 2
Group 3
Group I
Group 2
Group 3
Group 1,2,3
Group 1,2
I.D. L-7
14 585
76 491
13 604
18 585
24 610
28 416
29 555
58 478
3 418
83 548
27 400
30 585
51 308
68 334
81 712
PLASMA FERRITIN
ng per dl
FLIGHT ANIMALS
L-6 FD6 FD7 FD9 FDI0 FDI4 R+0 R+2 R+4 R+6
511 1070 1950 1330 483
459 1736 1328 1227 378
672 825 1002 739 639
664 795 574 654 796
884 1242 1322 t359 670
321 566 496 424
411 * 647 584
265 688 678 562
409 755 621 494
480 445 743 627
606 1066 531 446
463 581 487 395
462 1277 1696 479
146 1150 1106 434
185 1180 1011 454
Mean 575 638
SE 22 74
Mean 483 377
SE 30 38
Mean 468 372
SE 78 89
Mean 509 463
SE 29 50
Mean 516 491
SE 25 68
376 748 375
422 447 330
347 410 362
635 565 417
624 452 522
1134 1235 1062 593 481 524 401
172 226 151 73 62 62 33
614 637 538
68 41 36
1051 966 442
122 221 14
524
31
594
38
Group 1
Group 2
Group 3
125-I Albumin and 59-Fe injection on FD6
59-Fe and saline injection on FD9
59-Fe and EPO injection on FD9
Saline dilute_ -
Saline dilutcnt -
Saline dilutent -
total volume injected 1.2 ml
total volume injected 1.2 ml
total volume injected 1.2 ml
The elevated values for in-flight days may be due to a!l artifact of sample storage.
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